GENERAL Biocon Q2 Net Profit Declines 52% To ₹41 Cr; Revenue Up 2% At ₹4,389 Cr

Biocon Ltd, the Bengaluru-based global biopharmaceuticals company, reported a 52% year-on-year decline in consolidated net profit to ₹41 crore for the second quarter of FY27, compared with ₹85 crore in the corresponding quarter last fiscal. Consolidated revenue from operations increased 2% to ₹4,389 crore from ₹4,296 crore a year earlier. Consolidated EBITDA stood at ₹865 […]

CW Bureau · Nov 4, 2026

STARTUP/TECHNOLOGY Biocon Secures Yesintek Market Access In Nine More Countries

Biocon Ltd, a biopharmaceutical company, has signed a licensing agreement with Janssen Sciences Ireland to enable the commercialisation of Yesintek, its proposed biosimilar to Stelara (ustekinumab), in nine additional markets with immediate effect. The agreement covers Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan, expanding Biocon’s potential reach in the […]

CW Bureau · Oct 26, 2026

BANKING & FINANCE ICICI Pru MF Launches Nifty Pharma ETF As India Eyes $80-Bn Market

ICICI Prudential Asset Management Company has launched the ICICI Prudential Nifty Pharma ETF, an open-ended exchange-traded fund (ETF) tracking the Nifty Pharma Index, as India’s pharmaceutical industry positions itself for growth in complex generics, specialty medicines and contract manufacturing. The latest addition to the fund house’s sectoral ETF portfolio is designed to provide investors with […]

CW Bureau · Oct 10, 2026

GENERAL Pharma Sector Revenue Growth Seen At 11-13% This Fiscal: Crisil Ratings

India’s pharmaceutical sector is expected to see revenue growth accelerate to 11-13% this fiscal from 8% last fiscal, supported by stronger exports and firmer domestic demand, according to Crisil Ratings. However, the improvement in revenue is unlikely to translate fully into earnings as higher raw material, energy and freight costs are expected to put pressure […]

CW Bureau · Sep 24, 2026

GENERAL Biocon Arm Secures Positive EMA Opinion For Pertuzumab Biosimilar

Biocon Biologics Ltd, a wholly-owned subsidiary of Biocon Ltd, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation for its Pertuzumab biosimilar, Pebrilzo, for the treatment of HER2-positive breast cancer. The product, available as a 420 mg concentrate solution for […]

CW Bureau · Sep 21, 2026

GENERAL Biocon Biologics Secures Japan Govt Approval For Pegfilgrastim Biosimilar

Biocon Biologics Ltd, a wholly owned subsidiary of Biocon Ltd., has received marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, strengthening the company’s biosimilars portfolio in the Japanese market. The product is a biosimilar to Neulasta, a pegfilgrastim-based medicine used to reduce the risk of infection associated with […]

CW Bureau · Aug 25, 2026

GENERAL Amneal Pharma Completes Kashiv Bio Buy, Strengthens Biosimilars Platform

Amneal Pharmaceuticals Inc. has completed its acquisition of Kashiv BioSciences LLC, creating a fully integrated global biosimilars platform with capabilities spanning research, development, manufacturing and commercialisation. The acquisition brings together Kashiv’s biologics research, development and manufacturing capabilities with Amneal’s commercial scale, positioning biosimilars as a major long-term growth pillar for the company’s affordable medicines business. […]

CW Bureau · Aug 11, 2026

GENERAL Aurobindo Pharma Bets On Specialty Drugs, Biosimilars For Next Expansion

Aurobindo Pharma Ltd is doubling down on high-value specialty medicines, biosimilars and complex formulations while strengthening its manufacturing footprint and supply chain resilience as it charts its next phase of global growth. In his message to shareholders in the company’s Annual Report 2026, Vice Chairman & Managing Director K. Nithyananda Reddy said the company will […]

CW Bureau · Aug 4, 2026

GENERAL Biocon Launches Interchangeable Eye Drug Biosimilar Yesafili In US Market

Biocon Ltd has commercially launched Yesafili, its interchangeable biosimilar to blockbuster eye drug Eylea (aflibercept) 2 mg, in the United States, marking a significant expansion of its ophthalmology portfolio in the world’s largest pharmaceutical market. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of various retinal disorders, including age-related macular […]

CW Bureau · Aug 3, 2026

GENERAL Sun Pharma Receives Organon Shareholders Nod For $11.75-Bn Buy

Leading global pharmaceutical company Sun Pharmaceutical Industries Ltd has received shareholder approval from Organon & Co. for its proposed acquisition. The approval marks a key milestone towards completion of the transaction. Following the deal, Organon will become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA Inc., an indirect wholly owned subsidiary of Sun Pharma. […]

CW Bureau · Jul 24, 2026

GENERAL Lupin Banks On Biosimilars, Specialty Medicines To Power Next Expansion

Lupin Ltd is stepping up its focus on biosimilars, specialty medicines, complex generics and artificial intelligence (AI) as it builds the next phase of its growth strategy, according to Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta in a joint message to shareholders in the company’s Annual Report 2026. The leadership said years […]

CW Bureau · Jul 14, 2026

GENERAL Indian Pharma Firms To Gain Up To $5 Bn From Global Patent Cliff: CareEdge

Indian pharmaceutical companies are poised to benefit from a major global patent expiry cycle, with drugs generating nearly $142 billion in sales in CY25 set to lose exclusivity between 2026 and 2030, according to a report by CareEdge Ratings. The report estimates that the upcoming patent cliff could create a market opportunity of over $30-40 […]

CW Bureau · Jun 19, 2026